These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20408551)

  • 1. Lessons learned from herbal medicinal products: the example of St. John's Wort (perpendicular).
    Nahrstedt A; Butterweck V
    J Nat Prod; 2010 May; 73(5):1015-21. PubMed ID: 20408551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hypericin and hyperforin: bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect].
    Vacek J; Klejdus B; Kubán V
    Ceska Slov Farm; 2007 Apr; 56(2):62-6. PubMed ID: 17619301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
    Obach RS
    J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous determination of total hypericin and hyperforin in St. John's wort extracts by HPLC with electrochemical detection.
    Rückert U; Likussar W; Michelitsch A
    Phytochem Anal; 2007; 18(3):204-8. PubMed ID: 17500362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. St. John's wort.
    Lawvere S; Mahoney MC
    Am Fam Physician; 2005 Dec; 72(11):2249-54. PubMed ID: 16342849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. St John's wort, a herbal antidepressant, activates the steroid X receptor.
    Wentworth JM; Agostini M; Love J; Schwabe JW; Chatterjee VK
    J Endocrinol; 2000 Sep; 166(3):R11-6. PubMed ID: 10974665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
    Wang EJ; Barecki-Roach M; Johnson WW
    J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
    Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
    Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperforin in St. John's wort drug interactions.
    Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V
    Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. St. John's wort: role of active compounds for its mechanism of action and efficacy.
    Butterweck V; Schmidt M
    Wien Med Wochenschr; 2007; 157(13-14):356-61. PubMed ID: 17704987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of hyperforin in the pharmacological activities of St. John's Wort.
    Zanoli P
    CNS Drug Rev; 2004; 10(3):203-18. PubMed ID: 15492771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of St. John's wort on free radical production.
    Hunt EJ; Lester CE; Lester EA; Tackett RL
    Life Sci; 2001 Jun; 69(2):181-90. PubMed ID: 11441908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.
    Gödtel-Armbrust U; Metzger A; Kroll U; Kelber O; Wojnowski L
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):377-82. PubMed ID: 17593354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current St John's wort research from mode of action to clinical efficacy.
    Müller WE
    Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug?
    Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S
    Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining hyperforin and hypericin content in eight brands of St. John's wort.
    de los Reyes GC; Koda RT
    Am J Health Syst Pharm; 2002 Mar; 59(6):545-7. PubMed ID: 11908248
    [No Abstract]   [Full Text] [Related]  

  • 17. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
    Laakmann G; Schüle C; Baghai T; Kieser M
    Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():54-9. PubMed ID: 9684948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.
    Butterweck V; Christoffel V; Nahrstedt A; Petereit F; Spengler B; Winterhoff H
    Life Sci; 2003 Jun; 73(5):627-39. PubMed ID: 12770617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.
    Ng QX; Venkatanarayanan N; Ho CY
    J Affect Disord; 2017 Mar; 210():211-221. PubMed ID: 28064110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperforin and its analogues inhibit CYP3A4 enzyme activity.
    Lee JY; Duke RK; Tran VH; Hook JM; Duke CC
    Phytochemistry; 2006 Dec; 67(23):2550-60. PubMed ID: 17083953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.